Novo Nordisk A/S revised earnings guidance for the year 2024. For the year, the company expects sales growth to be 19% to 27% at CER compared to previous guidance of 18% to 26% at CER and operating profit growth is expected to be 22% to 30% at CER compared to previous guidance of 21% to 29% at CER. The updated sales outlook at CER reflects gross-to-net sales adjustments related to prior years in the US.

The guidance reflects expectations for sales growth in both North America Operations and International Operations, mainly driven by volume growth of GLP-1-based treatments for Obesity and Diabetes care. Continued pricing pressure within Diabetes and Obesity Care are included in the guidance.